|Mr. Daniel P. O'Day||Chairman & CEO||7.27M||N/A||1964|
|Mr. Andrew D. Dickinson||Executive VP & CFO||2.94M||N/A||1970|
|Ms. Deborah H. Telman||Executive VP of Corporate Affairs, General Counsel & Corporate Secretary||2.32M||N/A||1965|
|Ms. Johanna Mercier||Chief Commercial Officer||3.32M||N/A||1970|
|Dr. Merdad V. Parsey M.D., Ph.D.||Chief Medical Officer||3.07M||N/A||1963|
|Ms. Sandra Patterson||Senior VP, Corporate Controller & Principal Accounting Officer||N/A||N/A||1967|
|Ms. Jacquie Ross C.F.A.||Vice President of Investor Relations||N/A||N/A||N/A|
|Ms. Jyoti K. Mehra||Executive Vice President of Human Resources||N/A||N/A||1976|
|Dr. Linda Slanec Higgins Ph.D.||Senior Vice President of Research, Innovation & Portfolio||N/A||N/A||1962|
|Dr. Rudolf Ertl||Senior Vice President of Commercial Operations of Australia, Canada, Europe||N/A||N/A||1946|
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences, Inc.’s ISS governance QualityScore as of 28 November 2023 is 1. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 1; Compensation: 3.